18 June 2019 - Hemlibra has been included in the high-cost protection since autumn 2018 for the treatment of patients whose inhibitor development has not been lifted by repeated ITI treatments.
The company has come in with a basis for the patient groups within the approved indication that are not included in the high-cost protection.
TLV believes that prophylactic treatment with Hemlibra is not inferior to preventative treatment with factor VIII drugs in patients with severe haemophilia A.